Carlos Gil Ferreira

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony Mok, Yi‐Long Wu, Iveta Kudaba et al.|The Lancet|2019

Cited by 3.3kOpen Access

Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial

Adrianus J. de Langen, Melissa L. Johnson, Julien Mazières et al.|The Lancet|2023

Cited by 554Open Access

IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy

William D. Travis, Sanja Đačić, Ignacio I. Wistuba et al.|Journal of Thoracic Oncology|2020

Cited by 443Open Access

Colorectal Cancer: Epidemiology, Disease Mechanisms and Interventions to Reduce Onset and Mortality

Veronica Aran, Ana Paula Victorino, Luiz Cláudio Santos Thuler et al.|Clinical Colorectal Cancer|2016

Cited by 367

Apoptosis: target of cancer therapy.

Carlos Gil Ferreira, Mirjam T. Epping, Frank A.E. Kruyt et al.|PubMed|2002

Cited by 255

Recent knowledge on apoptosis has made it possible to devise novel approaches, which exploit this process to treat cancer. In this review, we discuss in detail approaches to induce tumor cell apoptosis, their mechanism of action, stage of development, and possible drawbacks. Finally, the obstacles yet to be overcome and the perspectives for potential clinical use of apoptosis-triggering approaches in cancer therapy in the future are assessed.

Carlos Gil Ferreira

Is this you? Claim your profile.

Top publicationsby citations